ZA200204585B - Process for the preparation of arylethanolamine derivatives having an anti-obesity and anti-diabetic properties. - Google Patents

Process for the preparation of arylethanolamine derivatives having an anti-obesity and anti-diabetic properties.

Info

Publication number
ZA200204585B
ZA200204585B ZA200204585A ZA200204585A ZA200204585B ZA 200204585 B ZA200204585 B ZA 200204585B ZA 200204585 A ZA200204585 A ZA 200204585A ZA 200204585 A ZA200204585 A ZA 200204585A ZA 200204585 B ZA200204585 B ZA 200204585B
Authority
ZA
South Africa
Prior art keywords
preparation
obesity
diabetic properties
arylethanolamine derivatives
arylethanolamine
Prior art date
Application number
ZA200204585A
Other languages
English (en)
Inventor
Lawrence Ronnie Maxwell
Alan Millar
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ZA200204585B publication Critical patent/ZA200204585B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Glass Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
ZA200204585A 1999-12-11 2002-06-07 Process for the preparation of arylethanolamine derivatives having an anti-obesity and anti-diabetic properties. ZA200204585B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9929297.1A GB9929297D0 (en) 1999-12-11 1999-12-11 Process

Publications (1)

Publication Number Publication Date
ZA200204585B true ZA200204585B (en) 2003-12-31

Family

ID=10866125

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200204585A ZA200204585B (en) 1999-12-11 2002-06-07 Process for the preparation of arylethanolamine derivatives having an anti-obesity and anti-diabetic properties.

Country Status (23)

Country Link
US (1) US6548523B2 (cs)
EP (1) EP1235788B1 (cs)
JP (1) JP4903964B2 (cs)
KR (1) KR100683614B1 (cs)
CN (1) CN1224609C (cs)
AT (1) ATE292110T1 (cs)
AU (1) AU769387B2 (cs)
BR (1) BRPI0016187B1 (cs)
CA (1) CA2394117C (cs)
CZ (1) CZ303143B6 (cs)
DE (1) DE60019157T2 (cs)
ES (1) ES2236020T3 (cs)
GB (1) GB9929297D0 (cs)
HK (1) HK1045988B (cs)
HU (1) HU229043B1 (cs)
IL (1) IL149585A0 (cs)
NO (1) NO323239B1 (cs)
NZ (1) NZ518795A (cs)
PL (1) PL200540B1 (cs)
PT (1) PT1235788E (cs)
TR (1) TR200201528T2 (cs)
WO (1) WO2001042195A1 (cs)
ZA (1) ZA200204585B (cs)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230147A1 (de) * 2001-10-09 2004-01-15 Profos Ag Verfahren zur unspezifischen Anreicherung von Bakterienzellen
US7158049B2 (en) * 2003-03-24 2007-01-02 Schlumberger Technology Corporation Wireless communication circuit
US8213085B2 (en) * 2008-01-18 2012-07-03 Visera Technologies Company Limited Image sensor device with high photosensitivity
WO2010118291A2 (en) 2009-04-10 2010-10-14 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
NZ607485A (en) 2010-08-03 2015-04-24 Altherx Inc Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
HK1204966A1 (en) 2012-02-09 2015-12-11 Velicept Therapeutics, Inc. Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder
US9956194B2 (en) 2014-12-03 2018-05-01 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
PL3365321T3 (pl) 2015-10-23 2024-03-25 B3Ar Therapeutics, Inc. Jon obojnaczy solabegronu i jego zastosowania

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1551260A (en) 1976-02-09 1979-08-30 Allen & Hanburys Ltd Phenylethanolamine derivatives
JP2577222B2 (ja) * 1987-04-10 1997-01-29 興和株式会社 新規な置換アニリド誘導体
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
GB9525121D0 (en) 1995-12-08 1996-02-07 Glaxo Group Ltd Chemical compounds
SK16282000A3 (sk) * 1998-05-01 2001-05-10 Abbott Laboratories Substituované beta-aminokyselinové inhibítory metionínaminopeptidázy-2
GB9812709D0 (en) * 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
AU769387B2 (en) 2004-01-22
CN1409700A (zh) 2003-04-09
CN1224609C (zh) 2005-10-26
GB9929297D0 (en) 2000-02-02
JP2003516383A (ja) 2003-05-13
HUP0203640A2 (hu) 2003-02-28
HU229043B1 (hu) 2013-07-29
DE60019157T2 (de) 2006-02-02
BR0016187A (pt) 2002-08-13
JP4903964B2 (ja) 2012-03-28
PL200540B1 (pl) 2009-01-30
PL356483A1 (en) 2004-06-28
TR200201528T2 (tr) 2002-09-23
CZ303143B6 (cs) 2012-05-02
KR100683614B1 (ko) 2007-02-16
HUP0203640A3 (en) 2003-08-28
HK1045988A1 (en) 2002-12-20
PT1235788E (pt) 2005-08-31
NO20022758D0 (no) 2002-06-10
US6548523B2 (en) 2003-04-15
NO20022758L (no) 2002-07-01
ES2236020T3 (es) 2005-07-16
HK1045988B (en) 2005-07-15
IL149585A0 (en) 2002-11-10
US20020198220A1 (en) 2002-12-26
BRPI0016187B1 (pt) 2016-08-02
CZ20022017A3 (cs) 2003-01-15
WO2001042195A1 (en) 2001-06-14
AU2191101A (en) 2001-06-18
CA2394117C (en) 2011-10-04
NZ518795A (en) 2004-02-27
DE60019157D1 (de) 2005-05-04
EP1235788B1 (en) 2005-03-30
EP1235788A1 (en) 2002-09-04
KR20020061636A (ko) 2002-07-24
NO323239B1 (no) 2007-02-05
ATE292110T1 (de) 2005-04-15
CA2394117A1 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
BE2017C018I2 (cs)
BG101250A (en) Salts of an anti-migraine indole derivative
HU0101336D0 (en) Process for the preparation of perindopril and their pharmaceutically acceptable salts
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
MY137562A (en) 2,5-dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12
CY1106743T1 (el) Μεθοδος παρασκευης θειαμεθοξαμης
GR3037080T3 (en) Naphthalene derivatives as prostaglandin i2 agonists
SE9203825L (sv) Dubbelt verkande inhibitorer foer no-syntas och cyklooxygenas, foerfarande foer framstaellning daerav och terapeutiska kompositioner innehaallande desamma
ATE230740T1 (de) Piperidinylpyrimidine derivate
WO2002072009A3 (en) Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
NZ334954A (en) Substituted heterocycles as anti-tumor agents
ZA200204585B (en) Process for the preparation of arylethanolamine derivatives having an anti-obesity and anti-diabetic properties.
GB0109122D0 (en) Novel compounds
MY138826A (en) 2,7-substituted indoles
IL108695A (en) Pharmaceutical composition comprising polyamine derivatives and some such novel compounds
MXPA04005484A (es) Procedimiento de preparacion de derivados de equinocandina.
AU2001260445A1 (en) Triterpenoid derivatives
MXPA01011955A (es) Aminoacidos policiclicos, fusionados, como agentes farmaceuticos.
IL113341A (en) Pharmaceutical compositions comprising aqueous intranasal antimigraine compounds together with chitosan and their preparation
EP1445262A8 (en) Peptide derivative, pharmaceutically acceptable salt thereof, process for producing the same, and use thereof
BG105999A (en) Treatment of osteoarthritis
WO2001090096A3 (en) Triterpenoid derivatives and their use as antiproliferative agents
WO2002042261A8 (en) PROCESS FOR PREPARING α-(3-ARYLTHIO)-ACETOPHENONES
MY120806A (en) Improved process for preparing pharmaceutically valuable norbenzomorphane derivatives.
MX9500363A (es) Monohiddrato de (e)-2'-desoxi-2'- (fluorometilen) citidina.